-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 27, Hengrui Medicine announced that its self-developed long-acting insulin/GLP-1 analog fixed-ratio compound preparation HR17031 injection has been approved for clinical use in China and is intended to be used for the treatment of type 2 diabetes
At present, two similar drugs have been approved by the FDA and the European Medicines Agency for the treatment of type 2 diabetes, namely Novo Nordisk’s Xultophy 100/3.
Novo Nordisk's Xultophy is a fixed-ratio compound preparation of insulin degludec/liraglutide.
Xultophy sales data over the years
Sanofi’s Soliqua is a fixed-ratio combination of risnatide/insulin glargine.
According to the Insight database, Hengrui currently has 6 innovative diabetes drugs under development, including the SGLT2 inhibitor Henggligliflozin, the DPP4 inhibitor Repagliptin, the GLP-1 analogue Noliglycopeptide, and the long-acting insulin INS068 (detailed (See picture below)
From the Insight database (http://db.
